Objective:To investigate the effects of ginkgo biloba tablets plus relevant mechanism on HPA axis in patients with steroid-dependent asthma.Methods:80 patients with steroid-dependent asthma were divided into control group and experimental group at random,40 cases in every group.The control group were treated with pulmicort respules(1 mg/d) ,patients in the experiment group were given ginkgo biloba tablets in addition to routine treatment(120 mg/d).The therapeutic courses were both 12 weeks.The effective rate of reducing hormone,lung function,the plasma concentrations of ACTH and COR and the levels of PBMC GCR were deter mined before and after treatment.Results:The effective rate of reducing hormone was 89.47%in experimental group,which was 66.67%in control group.There were significant difference at the tows groups(P<0.01).There were no significant difference at lung function,the plasma concentrations of ACTH and COR and the levels of PBMC GCR at pre-treatment( P>0.05).After treatment,the lung function, the levels of plasma concentrations of COR and the levels of PBMC GCR were increased significantly than control group( P<0.01,P<0.05),the levels of plasma concentrations of ACTH was decreased significantly than control group(P<0.01).There was a significant positive correlation between the value of FEV1/FVC and the plasma concentrations of COR,the levels of PBMC GCR( r=0.724,0.632, P<0.01).There was a significant negaitive correlation between the value of FEV1/FVC and the plasma concentrations of ACTH( r=-0.668,P<0.01).Conclusion:Ginkgo biloba tablets combined with routine treatment therapy can increase the effective rate of reducing hormone in patients with steroid-dependent asthma,which can improve the lung function maybe by regulate the HPA axis and upgrade the levels of GCR.

Objective To observe the effects of alprostadil injection on intestinal mucosal barrier function in patients with acute pancreatitis(AP). Methods Seventy-eight AP patients admitted in Department of Medicine in Yuhang District Second People's Hospital of Hangzhou City from May 2016 to March 2017 were divided into 2 groups using random number method,including 38 cases in the control group and 40 cases in the treatment group. Patients in the control group received routine treatment. Patients in the treatment group were given intravenous 10 μg/d alprostadil injection in addition to routine treatment continuously for 14 days. Another 40 healthy volunteers who underwent routine examination in the same period were enrolled as healthy control group. The scores of MCTSI and APACHEⅡwere recorded at admission and 2 days after the treatment. The levels of serum DAO, endotoxin (ET) and IFABP were detected by ELISA. Results There were no significant difference on the scores of MCTSI and APACHEⅡ, the levels of serum DAO, ET, IFABP before treatment between control and treatment group(P>0.05), but were increased significantly than those in the healthy control group(P<0.01). After treatment,the scores of MCTSI and APACHEⅡ,the levels of serum DAO, ET, IFABP were decreased significantly than those before treatment in two groups(P<0.05 or P<0.01), but the scores of MCTSI and APACHEⅡ, the levels of serum DAO, ET and IFABP were decreased significantly than those in the control group(3.78 ± 0.43)vs (5.89 ± 0.13),(5.65 ± 1.77)vs (9.05 ± 1.61),(2.18 ± 0.16)U/ml vs (3.22 ± 0.15)U/ml,(0.15 ± 0.06)EU/ml vs (0.25 ± 0.09)EU/ml,(62.01 ± 12.82)ng/L vs (85.43 ± 16.79)ng/L; all P<0.05). There was a significant positive correlation between serum DAO, ET, IFABP and the scores of MCTSI (P<0.01). There was a significant positive correlation between serum DAO, ET, IFABP and the scores of APACHEⅡ, too (P<0.01). Conclusions Patient with acute pancreatitis have obvious intestinal mucosal barrier injury. Alprostadil injection can improve clinical symptoms and the scores of MCTSI to a certain extent by protecting intestinal mucosal barrier function.

Objective To investigate the dynamical changes of serum SOCS-3 in patients with acute pancreatitis (AP) and discuss the potential clinical significance.Methods Seventy-five patients with AP admitted in Yuhang District Second People's Hospital of Hangzhou City from February 2015 to December 2016 were selected,who were divided into 2 groups according to disease severity:40 cases in mild AP (MAP) group and 35 cases in moderate and severe AP (MSAP + SAP) group.The levels of serum SOCS-3,IL-6 and TNF-α were determined by enzyme linked immunosorbent assay (ELISA) on the 1,3,5 and 7 day after admission.Thirty healthy people who were age and gender matched were included in the normal control group.Results The levels of serum SOCS-3,IL-6 and TNF-α in AP patients on the 1 day after admission were significantly increased than that in the control group (P ＜ 0.01 or P ＜ 0.05),which were gradually increased with the time,peaked on the 5 day and then started to decrease on 7 day after admission which was still higher than that on the 1 day after admission.The levels of serum SOCS-3,IL-6 and TNF-α in MSAP + SAP group were significantly higher than that in MAP group (P ＜0.01),and there were significant differences (F =112.80,P =0.001;F =170.21,P =0.000;F =112.82,P =0.000).Significant differences were also found among different time points between two groups (F =258.38,P =0.000;F =4.82,P =0.000;F =5.52,P =0.001).Additionally,the significantly positive correlations of SOCS-3 with IL-6 and TNF-α were found (r=0.785,r=0.828,both P＜0.01).Conclusions SOCS-3 may participate in early excessive inflammatory reactions in AP.Dynamic detection of SOCS-3 may be helpful for AP clinical classification and prognosis evaluation.

Objective: To analyze the nucleic acid load of human parvovirus B19 in major commercially available blood products in China, including human albumin, human intravenous immunoglobulin, human rabies immunoglobulin and various coagulation factor products, aiming to provide evidence for improving blood product manufacturing processes and quality control of source plasma. Methods: A total of 98 batches of coagulation factor products were tested for human parvovirus B19 nucleic acid using real-time fluorescent quantitative PCR, including 42 batches of human prothrombin complex, 35 batches of human coagulation factor Ⅷ, and 21 batches of human fibrinogen. Additionally, 6 batches of human albumin, 6 batches of human intravenous immunoglobulin, and 38 batches of human rabies immunoglobulin were tested for human parvovirus B19 nucleic acid. Results: Human parvovirus B19 nucleic acid were undetectable in human albumin, human intravenous immunoglobulin and human rabies immunoglobulin. Among the 98 batches of coagulation factor products tested for human parvovirus B19 nucleic acid, B19 nucleic acid reactivity rate was 69.0% (29/42) for human prothrombin complex batches, but nucleic acid concentration were all significantly lower than 10 IU/mL. The reactivity rate of B19 nucleic acid in 35 batches of human coagulation factor Ⅷ was 48.6% (17/35), with nucleic acid concentration all below 10 IU/mL. The reactivity rate of B19 nucleic acid in 21 batches of human fibrinogen was 61.9% (13/21), with nucleic acid concentration all below 10 IU/mL. Conclusion: No human parvovirus B19 has been detected in human albumin, human intravenous immunoglobulin, or human rabies immunoglobulin. Human parvovirus B19 nucleic acid may exist in commercially available coagulation factor products, highlighting the need for enhanced screening of human parvovirus B19 nucleic acid in these products. It is also recommended that B19 viral nucleic acid testing be conducted on source plasma, particularly for coagulation factor products.

Objective: To analyze the nucleic acid load of human parvovirus B19 in major commercially available blood products in China, including human albumin, human intravenous immunoglobulin, human rabies immunoglobulin and various coagulation factor products, aiming to provide evidence for improving blood product manufacturing processes and quality control of source plasma. Methods: A total of 98 batches of coagulation factor products were tested for human parvovirus B19 nucleic acid using real-time fluorescent quantitative PCR, including 42 batches of human prothrombin complex, 35 batches of human coagulation factor Ⅷ, and 21 batches of human fibrinogen. Additionally, 6 batches of human albumin, 6 batches of human intravenous immunoglobulin, and 38 batches of human rabies immunoglobulin were tested for human parvovirus B19 nucleic acid. Results: Human parvovirus B19 nucleic acid were undetectable in human albumin, human intravenous immunoglobulin and human rabies immunoglobulin. Among the 98 batches of coagulation factor products tested for human parvovirus B19 nucleic acid, B19 nucleic acid reactivity rate was 69.0% (29/42) for human prothrombin complex batches, but nucleic acid concentration were all significantly lower than 10 IU/mL. The reactivity rate of B19 nucleic acid in 35 batches of human coagulation factor Ⅷ was 48.6% (17/35), with nucleic acid concentration all below 10 IU/mL. The reactivity rate of B19 nucleic acid in 21 batches of human fibrinogen was 61.9% (13/21), with nucleic acid concentration all below 10 IU/mL. Conclusion: No human parvovirus B19 has been detected in human albumin, human intravenous immunoglobulin, or human rabies immunoglobulin. Human parvovirus B19 nucleic acid may exist in commercially available coagulation factor products, highlighting the need for enhanced screening of human parvovirus B19 nucleic acid in these products. It is also recommended that B19 viral nucleic acid testing be conducted on source plasma, particularly for coagulation factor products.